Rights and permissions
About this article
Cite this article
Dasatinib, nilotinib effective for imatinib-resistant CML and ALL. Inpharma Wkly. 1543, 6 (2006). https://doi.org/10.2165/00128413-200615430-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200615430-00015